|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
Chest, Vol 105, 673-680, Copyright © 1994 by American College of Chest Physicians
ARTICLES |
SD Anderson, JI du Toit, LT Rodwell and CR Jenkins
Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, Australia.
STUDY OBJECTIVE: To investigate the acute effect of sodium cromoglycate on airway responses to 4.5 percent saline aerosol challenge, before and during treatment with inhaled budesonide--a corticosteroid. DESIGN: Open study, with a total of five visits, two before budesonide treatment, and three follow-up visits, two between 5 and 6 weeks and one at more than 11 weeks. SETTING: Referral-based Respiratory Investigation Unit at Royal Prince Alfred Hospital, a major Sydney- based teaching hospital. PATIENTS: Eleven patients with asthma (ten atopic), with a PD20 FEV1 to 4.5 percent saline aerosol challenge and about to commence inhaled budesonide for treatment of their asthma. INTERVENTIONS: The 40 mg of sodium cromoglycate was inhaled before a 4.5 percent NaCl challenge, both before and after regular (36 +/- 9 d) treatment with budesonide (1,000 micrograms/d). The final challenge was repeated in ten subjects after 11 weeks or more of treatment with budesonide. MEASUREMENTS AND RESULTS: Sensitivity to 4.5 percent saline aerosol was measured as the dose of saline aerosol required to induce a 20 percent fall in FEV1 (PD20). Reactivity was measured as the dose- response slope by taking the percent fall in FEV1 and dividing it by the dose required to induce the fall. On the control day the geometric mean PD20 (95 percent CI) for 4.5 percent saline aerosol was 2.8 (1.4 to 5.4) and the dose response slope (DRS) 5.6 (2.9-11.1). An acute dose of sodium cromoglycate reduced sensitivity (PD20) by 8-fold and reactivity (DRS) 12.3-fold. This effect was similar in magnitude to that measured after regular treatment with budesonide alone. When sodium cromoglycate was given during treatment with budesonide, the PD20 was reduced 16-fold and the DRS 42-fold, and this was greater than the reduction with budesonide taken for 3 months (p < 0.03, p < 0.05 respectively). CONCLUSIONS: Sodium cromoglycate inhibits responses to 4.5 percent saline aerosol and has additional benefits to those conferred by aerosol steroids. The mechanism for responsiveness to saline aerosol and efficacy of these drugs may relate to alteration in chloride ion channel regulation by inflammation.
This article has been cited by other articles:
![]() |
G.F. Joos and B. O'Connor Indirect airway challenges Eur. Respir. J., June 1, 2003; 21(6): 1050 - 1068. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. BARNES, S. PEDERSEN, and W. W. BUSSE Efficacy and Safety of Inhaled Corticosteroids . New Developments Am. J. Respir. Crit. Care Med., March 1, 1998; 157(3): S1 - 53. [Full Text] [PDF] |
||||
![]() |
S. D. ANDERSON, J. BRANNAN, J. SPRING, N. SPALDING, L. T. RODWELL, K. CHAN, I. GONDA, A. WALSH, and A. R. CLARK A New Method For Bronchial-provocation Testing in Asthmatic Subjects Using a Dry Powder of Mannitol Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 758 - 765. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |